CClinicalTrials.gg
Sign In
Active, not recruitingNCT05800093PREDICT-CVDUpdated Oct 2, 2025

Proteomics and Genomics Combined With CT to Predict CVD

An observational study in Coronary Artery Disease Progression, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Active, not recruiting at 1 site in Netherlands. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Observational

From the registry’s dates

  • Primary completion was expected by Jan 2026, 8 months ago, but the record still lists the study as active, not recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
310
Ages
50 Years to 75 Years
Sex
All
01

Study summary

This study evaluates plaque progression and characteristics in patients with coronary atherosclerosis.

02

Conditions studied

  • Coronary Artery Disease Progression
03

In context

Lead sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 512 studies on the registry; 178 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Adult patients between 50 and 75 years old with nonobstructive coronary artery disease

Inclusion criteria

  • Adult patients between 50 and 75 years old
  • Subjects at intermediate to high risk for ASCVD
  • Asymptomatic patients without cardiac chest pain
  • Evidence of atherosclerosis on baseline CCTA

Exclusion criteria

Exclusion Criteria:

  • Renal insufficiency, defined as eGFR \< 30 ml/min
  • History of cardiovascular events (myocardial infarction, peripheral artery disease and ischemic stroke)
  • Use of lipid lowering therapy other than statin, ezetimibe or bempedoic acid monotherapy
  • Change in lipid lowering therapy in the last 6 months
  • Use of more than two antihypertensive agents
  • No coronary atherosclerosis at baseline imaging
  • Active malignancy requiring treatment
  • Atrial fibrillation
  • Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
  • Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
310 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Coronary Artery Disease Progression

    Time frame: Through study completion, between 130-156 weeks

Secondary outcomes

  1. Presence of obstructive stenosis

    Time frame: Through study completion, between 130-156 weeks

  2. Progression in number of significant (>50%) and severe (>70%) stenoses

    Time frame: Through study completion, between 130-156 weeks

  3. Total plaque volume progression

    Time frame: Through study completion, between 130-156 weeks

  4. Calcified plaque volume progression

    Time frame: Through study completion, between 130-156 weeks

  5. Non-calcified plaque volume progression

    Time frame: Through study completion, between 130-156 weeks

  6. Low-attenuation plaque volume progression

    Time frame: Through study completion, between 130-156 weeks

  7. Change in Pericoronary Adipose Tissue CT-Attenuation

    Time frame: Through study completion, between 130-156 weeks

  8. CAD-RADS progression (yes/no)

    Time frame: Through study completion, between 130-156 weeks

  9. Progression in number of high-risk plaque characteristics (yes/no)

    Time frame: Through study completion, between 130-156 weeks

07

Study locations

1 site
  • Amsterdam UMC, location AMC
    Amsterdam, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05800093
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Responsible party
E.S.stroes (Principal Investigator, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Apr 5, 2023
Start date
Jan 12, 2023
Primary completion
Jan 30, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Oct 2, 2025

Study contacts

Erik SG Stroes, MD PhD
principal investigator · Amsterdam UMC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Start the discussion